LearnGlossaryMarketStocksSuperinvestorsSign in

ECOR

electroCore, Inc.

Healthcare · $98M market cap

Verdict

We can't put a fair value on ECOR right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-41.9% a year✗
Sales growth57.1% a year✓
Free cash flow growth—?
Return on invested capital-74.1%✗

Follow ECOR

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 8, 2026: no open-market purchases and 9 other filings (stock awards, tax withholding and similar). Why purchases matter

Other filings

Fox Michael

See Remarks · 2026-09-11

Award

$49K

GANDOLFO JOHN P

director · 2026-09-09

Award

11,123 shares

Errico Thomas J.

director · 2026-09-09

Award

15,572 shares

Goldstein Julie Ann

director · 2026-09-09

Award

11,123 shares

Bonfiglioli Elena

director · 2026-09-09

Award

11,123 shares

Show all 9 other filings

Wilber Patricia

director · 2026-09-09

Award

11,123 shares

Theofilos James Charles

director · 2026-09-09

Award

11,123 shares

Lev Joshua S.

See Remarks · 2026-09-08

Award

55,000 shares

Fox Michael

See Remarks · 2026-09-08

Award

55,000 shares

About electroCore, Inc.

electroCore, Inc. is a commercial-phase medical device enterprise whose focus lies in developing and bringing to market a variety of non-invasive vagus nerve stimulation (nVNS) therapies. Currently, the firm is advancing gammaCore, a prescription-only nVNS therapy specifically engineered for adults to acutely treat the discomfort associated with both migraine and episodic cluster headaches. Its flagship offering…

Medical - Devices

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works